Publicaciones en colaboración con investigadores/as de Hospital Clinic Barcelona (12)

2022

  1. FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology

    Blood Advances, Vol. 6, Núm. 2, pp. 690-703

  2. Laboratory Cross-Comparison and Ring Test Trial for Tumor BRCA Testing in a Multicenter Epithelial Ovarian Cancer Series: The BORNEO GEICO 60-0 Study

    Journal of Personalized Medicine, Vol. 12, Núm. 11

  3. NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial

    Cancers, Vol. 14, Núm. 20

2021

  1. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma

    Blood, Vol. 137, Núm. 1, pp. 49-60

2020

  1. Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

    Blood, Vol. 135, Núm. 26, pp. 2375-2387

  2. Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma

    Leukemia, Vol. 34, Núm. 11, pp. 3007-3018

2017

  1. Differentiation stage of myeloma plasma cells: Biological and clinical significance

    Leukemia, Vol. 31, Núm. 2, pp. 382-392

2016

  1. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: A new model to understand chemoresistance

    Blood, Vol. 127, Núm. 15, pp. 1896-1906

2005

  1. Oxidation of specific methionine and tryptophan residues of apolipoprotein A-I in hepatocarcinogenesis

    Proteomics, Vol. 5, Núm. 18, pp. 4964-4972

2004

  1. Genetic diagnosis by comparative genomic hybridization in adult de novo acute myelocytic leukemia

    Cancer Genetics and Cytogenetics, Vol. 153, Núm. 1, pp. 16-25

  2. Methylthioadenosine phosphorylase gene expression is impaired in human liver cirrhosis and hepatocarcinoma

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1690, Núm. 3, pp. 276-284

2003

  1. Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation

    British Journal of Haematology, Vol. 120, Núm. 3, pp. 500-504